• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » QPS Delaware expands translational medicine capabilities

QPS Delaware expands translational medicine capabilities

August 9, 2017
CenterWatch Staff

QPS Holdings, a full-service GLP/GCP-compliant CRO providing testing services to support preclinical and clinical research and development, is investing in additional technical personnel and laboratory capacity for translational medicine at its flagship Delaware Technology Park facility. This significant expansion will enable QPS Delaware to process the high sample volumes required for phase III clinical drug trials.

Once complete, new hiring is projected to increase laboratory staff from 57 to 88. Most of these additions are to be technical personnel and will raise the number of analysis teams from seven to eleven. The relationship-building, one-client-one-team approach is a hallmark of QPS efficiency. A special working group to handle regulatory authorities’ rising demand for neutralizing antibody assays has also been added.

To accommodate the increase in technical operations, QPS has expanded the square footage devoted to immunobioanalysis and cell culture, as well as the protein mass spectrometry area.

“For a long time, clients have known us as the boutique CRO—a high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation,” said John L. Kolman, Ph.D., VP and Global Head of Translational Medicine at QPS. “Now we are in a position to follow through and support phase III, even for very large studies.”

Translational Medicine is a growing, multi-disciplinary science focused on speeding translation of experimental discoveries into effective diagnostic tools and therapies.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing